Dr. Bing Lou Wong

Bing is a seasoned executive in the commercialization of biologics. During his tenure as Acting Director at the New England Enzyme Center and Associate Professor at Tufts Medical School of Boston, he prepared hundreds of biologics such as the first clinical batch of rDNA Gamma interferon, and scaled up the production of ß-Glucocerebrosidase currently marketed as Ceredase® by Genzyme (NASDAQ: GENZ). He was a founding member of Biopure (NASDAQ: BPUR), where he served as CTO and Senior Vice President responsible for the development of Cephalosporin antibiotics and Hemoglobin-based oxygen carriers (artificial blood): Hemopure® and Oxyglobin®, and strategic business ventures and fund raising activities.